OTCMKTS:BCYP

Big Cypress Acquisition (BCYP) Stock Forecast, Price & News

$8.44

-2.01 (-19.23%)

(As of 10/22/2021)

Compare

Today's Range: $8.21
▼
$12.90
50-Day Range: $8.44
▼
$8.44
52-Week Range: $8.21
▼
$12.90

Volume: 15.34 million shs
Average Volume: 160,982 shs
Market Capitalization: $124.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Insider Trades Institutional Ownership Headlines

About Big Cypress Acquisition (OTCMKTS:BCYP) Stock

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.

Receive BCYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Big Cypress Acquisition and its competitors with MarketBeat's FREE daily newsletter.

BCYP Stock News Headlines

April 4, 2023 | forbes.com

Big Ass Fans

April 2, 2023 | americanbankingnews.com

Big Cypress Acquisition (OTCMKTS:BCYP) Stock Price Passes Below Two Hundred Day Moving Average of $8.44

June 6, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

March 22, 2023 | americanbankingnews.com

Analyzing Relay Therapeutics (NASDAQ:RLAY) & Big Cypress Acquisition (OTCMKTS:BCYP)

March 2, 2022 | reuters.com

SAB Biotherapeutics Inc

October 21, 2021 | finance.yahoo.com

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

October 4, 2021 | finance.yahoo.com

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

September 28, 2021 | finance.yahoo.com

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

June 6, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

September 24, 2021 | finance.yahoo.com

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

September 22, 2021 | finance.yahoo.com

SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

September 15, 2021 | finance.yahoo.com

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

September 8, 2021 | finance.yahoo.com

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

August 11, 2021 | barrons.com

Big Cypress Acquisition Corp.

August 11, 2021 | finance.yahoo.com

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

August 10, 2021 | nasdaq.com

Big Cypress Acquisition Corp. Common stock (BCYP)

July 15, 2021 | in.finance.yahoo.com

STMP Jul 2021 300.000 put

July 15, 2021 | finance.yahoo.com

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics

July 10, 2021 | finance.yahoo.com

Lifshitz Law Firm, P.C. Announces Investigation of ALTA, BCYP, IKNX and STMP

July 7, 2021 | finance.yahoo.com

Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics

June 28, 2021 | finance.yahoo.com

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: CITIC Capital Acquisition Corp. (NYSE - CCAC), Thimble Point Acquisition Corp. (Nasdaq - THMA), Big Cypress Acquisition Corp. (Nasdaq - BCYP)

June 25, 2021 | apnews.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Big Cypress Acquisition Corp.

June 25, 2021 | feeds.benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Big Cypress Acquisition Corp. Merger

June 22, 2021 | finance.yahoo.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Big Cypress Acquisition Corp. (Nasdaq - BCYP)

June 22, 2021 | finance.yahoo.com

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases

June 11, 2021 | investing.com

Big Cypress Acquisition Corp (BCYP)

April 26, 2021 | msn.com

Inside Primary Wave’s $1.5 Billion Hit Factory

See More Headlines

BCYP Price History

30 days | 90 days | 365 days | Advanced Chart

BCYP Company Calendar

Last Earnings: 11/11/2014
Today: 6/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BCYP
CUSIP: N/A
CIK: 1399587
Web: www.bluecalypso.com
Phone: 305-204-3338
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.13
Quick Ratio: 6.13

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 14,792,000
Free Float: N/A
Market Cap: $124.84 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Samuel J. Reich (Age 46)
CEO, CFO & Director

Key Competitors

View All Competitors

BCYP Stock - Frequently Asked Questions

How have BCYP shares performed in 2023?: Big Cypress Acquisition's stock was trading at $8.44 at the start of the year. Since then, BCYP shares have increased by 0.0% and is now trading at $8.44.
View the best growth stocks for 2023 here.
How were Big Cypress Acquisition's earnings last quarter?: Big Cypress Acquisition Corp. (OTCMKTS:BCYP) posted its quarterly earnings data on Tuesday, November, 11th. The technology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The technology company earned $0.31 million during the quarter, compared to the consensus estimate of $0.21 million.
What other stocks do shareholders of Big Cypress Acquisition own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Big Cypress Acquisition investors own include Co-Diagnostics (CODX), iBio (IBIO), PharmaCyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Ascent Solar Technologies (ASTI), BioRestorative Therapies (BRTX), Digital Ally (DGLY) and FuelCell Energy (FCEL).
What is Big Cypress Acquisition's stock symbol?: Big Cypress Acquisition trades on the OTCMKTS under the ticker symbol "BCYP."

How do I buy shares of Big Cypress Acquisition?: Shares of BCYP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Big Cypress Acquisition's stock price today?: One share of BCYP stock can currently be purchased for approximately $8.44.
How much money does Big Cypress Acquisition make?: Big Cypress Acquisition (OTCMKTS:BCYP) has a market capitalization of $124.84 million.
How can I contact Big Cypress Acquisition?: Big Cypress Acquisition's mailing address is 101 W. RENNER RD., RICHARDSON TX, 75082. The official website for the company is www.bluecalypso.com. The technology company can be reached via phone at 305-204-3338 or via email at investors@bluecalypso.com.

This page (OTCMKTS:BCYP) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial